Moderna-Merck Cancer Vaccine Reduces Recurrence Risk by 49% in Phase 3 Trial Aug 20, 2026 Moderna Shares Surge Nearly 177% After Personalised Cancer Vaccine Succeeds in Phase 3 Trial Moderna shares surged…
